Amyris PT Raised to $3.50 at Cowen and Company (AMRS)
Investment analysts at Cowen and Company hoisted their price target on shares of Amyris (NASDAQ:AMRS) from $3.00 to $3.50 in a note issued to investors on Friday. Cowen and Company’s price objective suggests a potential downside of 5.15% from the stock’s previous close.
Amyris (NASDAQ:AMRS) opened at 3.70 on Friday. Amyris has a 1-year low of $2.17 and a 1-year high of $6.11. The stock has a 50-day moving average of $3.7 and a 200-day moving average of $3.75. The company’s market cap is $291.0 million.
Amyris (NASDAQ:AMRS) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.10. The company had revenue of $9.30 million for the quarter, compared to the consensus estimate of $12.36 million. During the same quarter in the previous year, the company posted ($0.34) earnings per share. The company’s revenue for the quarter was down 13.9% on a year-over-year basis. Analysts expect that Amyris will post $-1.06 EPS for the current fiscal year.
Separately, analysts at Stifel Nicolaus initiated coverage on shares of Amyris in a research note on Wednesday, May 28th. They set a “hold” rating on the stock.
Amyris, Inc, formerly Amyris Biotechnologies, Inc develops and provides renewable compounds for a variety of markets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.